8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 13, 2020)

Filed January 13, 2020For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) has reported preliminary fourth quarter and full year 2019 financial results, focusing on net product revenues for its key drugs, ONPATTRO® and GIVLAARI™. ONPATTRO® demonstrated significant revenue generation, with approximately $56 million in Q4 2019 and $166 million for the full year. GIVLAARI™, recently approved in the US in late November 2019, generated approximately $0.2 million in revenue by year-end, indicating the early stages of its commercial launch. Furthermore, the company provided an update on its strong liquidity position, with preliminary cash, cash equivalents, marketable securities, and restricted investments totaling approximately $1.5 billion as of December 31, 2019. Investors should note that these figures are preliminary and unaudited, subject to adjustments, with complete financial results expected in February 2020. This filing provides an early look at commercial traction for Alnylam's therapeutic advancements.

Key Highlights

  • 1Preliminary Q4 2019 global net product revenues for ONPATTRO® were approximately $56 million.
  • 2Full year 2019 global net product revenues for ONPATTRO® reached approximately $166 million.
  • 3GIVLAARI™ generated preliminary global net product revenues of approximately $0.2 million from its US launch in late November 2019 through year-end.
  • 4Company reported preliminary total cash, cash equivalents, marketable securities, and restricted investments of approximately $1.5 billion as of December 31, 2019.
  • 5These financial results are preliminary and unaudited, subject to potential adjustments.
  • 6Complete financial results for the fourth quarter and full year 2019 are expected in February 2020.

Frequently Asked Questions

The primary revenue driver was ONPATTRO®, which generated approximately $56 million in preliminary net product revenues for the fourth quarter of 2019. GIVLAARI™ also began contributing, albeit with minimal revenue of approximately $0.2 million due to its recent US launch.

ONPATTRO® showed solid commercial performance, achieving approximately $166 million in global net product revenues for the full year 2019, with a notable $56 million in the fourth quarter. This indicates steady growth and market acceptance.

Alnylam maintains a strong liquidity position, reporting preliminary cash, cash equivalents, marketable securities, and restricted investments of approximately $1.5 billion as of December 31, 2019. This provides significant financial flexibility for ongoing operations and future growth.

No, the reported revenue and cash figures are preliminary and unaudited. They are approximations provided in advance of the company's complete financial results announcement in February 2020 and are subject to potential adjustments.